[2021] Ticagrelor Market Booming with Top PLAYERS: C.H. Boehringer Sohn AG & Ko. KG, Pfizer, Eli Lilly and Company, AstraZeneca

High prevalence of coronary heart disease is expected to aid in growth of the global ticagrelor market. Ticagrelor is a drug used for the treatment of coronary heart disease (CHD). It has shown some effectiveness in acute myocardial ischemia. Ticagrelor should only be prescribed with non-steroidal anti-inflammatory drugs such as aspirin. Prescribing ticagrelor at a dosage between 75 and 160 mg/day may not be as effective as clopidogrel when used alone.

Request Here Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2515

Ticagrelor is used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome. According to ‘Heart disease and stroke statistics—2019 update’, a report from the American Heart Association, published in 2019, coronary artery disease accounted for 365,914 deaths in the U.S. in 2017. Thus, high prevalence of coronary artery disease is also expected to aid in growth of the global ticagrelor market.

Ticagrelor has been approved to treat myocardial ischemia and acidosis (receding cardiomyopathy), but has not yet been approved for use in the treatment of cerebro-vascular accident (stroke) or multiple sclerosis (MS) and degenerative or life-altering diseases. The Food and Drug Administration (FDA) has approved this new indication because the mechanism of action is thought to target myocardium rather than the brain. Ticagrelor can reduce blood pressure, decrease muscle tone and enhance muscle flexibility. It can increase ambulatory breathing. This drug is currently available in the U.S ticagrelor market.

Key Players of Ticagrelor Market:

The key Ticagrelor industry leaders profiled in the report include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.. These key players have adopted strategies, such as product portfolio expansion, mergers & acquisitions, agreements, geographical expansion, and collaborations, to enhance their market penetration

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report

Buy Now with Discount for Premium Report : https://www.coherentmarketinsights.com/promo/buynow/2515

Ticagrelor Market Segmentation

Based on type, the absolute Ticagrelors segment contributed to the largest share in 2020, accounting for more than two-fifths of the total share, and is estimated to maintain its dominant position during the forecast period.

By Strength:

60 mg
90 mg
By Indication:

Acute Coronary Syndrome
Ischemic Stroke
By Distribution Channel:

Hospital pharmacies
Retail Pharmacies
Online Pharmacies
Ticagrelor Market regional analysis includes:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

Europe (Turkey, Germany, Russia, United Kingdom, Italy, France, etc.)

North America (United States, Mexico and Canada).

South America (Brazil etc.)

Middle East and Africa (GCC countries and Egypt).

In the market segmentation by manufacturers, the report covers the following companies: C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.

Get Sample PDF Brochure@ https://www.coherentmarketinsights.com/insight/request-pdf/2515

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Note – In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights' market intelligence service provides a comprehensive view of the market, using the existing sources of information. Our market intelligence service addresses key challenges of a market; helps in finding opportunities across various industries, and helps potential investors and partners to support the strategic decision-making process.

This release was published on openPR.